PRIMARY PERITONEAL CANCER
Clinical trials for PRIMARY PERITONEAL CANCER explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL CANCER trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for women with resistant ovarian cancer: RC88 shows promise
Disease control CompletedThis study tested a new drug called RC88 in 43 women whose ovarian, fallopian tube, or peritoneal cancer had stopped responding to platinum-based chemotherapy. The goal was to see if RC88 could shrink tumors and how safe it was. Participants had already tried at least three other…
Matched conditions: PRIMARY PERITONEAL CANCER
Phase: PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
New drug cocktail shows promise for Hard-to-Treat ovarian cancer
Disease control CompletedThis study tested a combination of two drugs, pamiparib and surufatinib, in 29 women with ovarian cancer that had stopped responding to platinum chemotherapy and had already been treated with a PARP inhibitor. The goal was to see if the combo could slow or stop cancer growth. The…
Matched conditions: PRIMARY PERITONEAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Immunotherapy combo shows promise in tough ovarian cancer
Disease control CompletedThis early-phase study tested whether adding the immunotherapy drugs nivolumab (with or without ipilimumab) to standard chemotherapy could safely treat advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. 27 patients received the combination before an…
Matched conditions: PRIMARY PERITONEAL CANCER
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
Ovarian cancer drug rucaparib: Real-World results match clinical trials
Knowledge-focused CompletedThis study reviewed medical records of 51 women with ovarian, fallopian tube, or primary peritoneal cancer who received the drug rucaparib in regular clinical practice in Spain. Researchers looked at patient history, side effects, dosing, and how well the drug controlled the canc…
Matched conditions: PRIMARY PERITONEAL CANCER
Sponsor: Grupo Español de Investigación en Cáncer de Ovario • Aim: Knowledge-focused
Last updated May 22, 2026 13:51 UTC